Our vision is to better guide targeted treatment selection in cancers with next-generation diagnostic tests. The SCALPEL cell-based test is a minimally invasive and highly informative assay that performs single cell profiling of oncogenic signaling characteristics. By profiling certain pertinent features of cancer cells, the assay provides information that can guide treatment decisions. It promises to enhance the ability to select targeted therapies based on cell-based characteristics and tumor stage. The test is designed to analyze the cellular ecosystem, including the cancerous cells and cell types comprising the anti-tumor immune response. An integral goal is to accurately detect actionable disease. The Eyelis analytics aim to support high dimensional data visualization of cell-specific protein expression profiling, ultimately to integrate the data into “multi-omics” approach to characterizing hematologic cancers.
In acute and chronic leukemia treated with signaling pathway inhibitors, the test can more accurately identify residual leukemic progenitors. In cancers treated with immunotherapies, the profiling of immune cell milieu can improve monitoring of response to treatment. Predictive models are based on knowledge of the cellular ecosystem and targeted protein and gene expression analysis.
~Jitakshi De, MD
Jitakshi De, President & CEO
MD, FCAP, FASCP
Dr. De is a Physician Scientist and Entrepreneur, and Founder of Deepath Medical Diagnostics (DeepathMD). She earned her M.D. from Duke University and holds a Bachelors in Biology from University of North Carolina at Chapel Hill. De completed her residency in Anatomic and Clinical Pathology from University of Texas at Houston (’03 – ’07) and a fellowship in Hematopathology from University of Michigan (’08 – ’09).
Her clinical and translational research experiences include:
’93-’94: Use of a dicentric chromosome breakage assay in S. cerevisiae for identification of kinetochore proteins of functional significance.
’97-’98: Cloning of the unusual class of ARE mRNA-regulating CCCH tandem zinc finger proteins in X. laevis, including identification of a novel vertebrate member, XC3H-4.
’00-’02: LC-MS/MS analysis to compare the cell surface proteome of FACS-purified peripheral blood CD4 and CD8 T cell subsets.
’04-’05 Assessment of prognostic factors relevant in chronic lymphocytic leukemia (CLL) treated with a combination chemoimmunotherapy.
’06-’07: Identification of an immunophenotypic correlate (i.e. diminished aberrant CD19 expression) of KIT-activating mutations in acute myeloid leukemia with t(8;21)/AML1-ETO.
’07-’08: Phospho-specific immunocytochemistry analysis of growth factor-induced signaling pathway activation in FACS-purified CD133+ hematopoietic stem cells.
’08-’09: Morphoproteomic analysis of survival pathways in classical Hodgkin lymphoma (cHL) cells and microenvironment.
’12-’15: Immunophenotypic characterization of oncogenic pathways in chronic myeloid leukemia (CML) progenitor cell types by extensively multiplexed cytometry.
’13-present: Development of advanced software analysis tools for highly multiparametric cytometry based on time-of-flight mass spectrometry detection of rare earth metal-tagged antibodies.
She brings valuable industry experience in flow cytometry and mass spectrometry-based immunophenotyping with high dimensional analytics for both biomarker discovery and cancer diagnostics.
Dr. De was a recipient of the Howard Hughes Medical Institute Student Research Fellowship (1997 – 1998), CAP Fellowship in Hematopathology (06/06 – 07/06), and the Becton Dickinson Biosciences Stem Cell Research Award (Summer 2013) . Her research interests include functional identification of cell types and the immunologic response in neoplastic conditions. She is a Fellow of the American Society of Clinical Pathology and the College of American Pathologists. Click here for De’s CV
Paul H. Kane, BSEE, Lead Algorithm Engineer
Paul comes with an extensive background in signal processing and analysis of biomedical data from magnetic resonance spectroscopy and mass spectrometry. His expertise is in continuous problem solving through the application of advanced techniques combining signal and data processing, image analysis and analytical mechanics. He applies intuition and a solid background in engineering and physics fundamentals for pattern classification of high dimensional cytometry data.
BOARD OF ADVISORS
John K. Choi, MD, PhD
Dr. Choi is an Associate Faculty of St. Jude Children’s Research Hospital. He completed his medical education and post-doctoral studies from University of Pennsylvania, and was on faculty at Children’s Hospital of Philadelphia prior to joining St. Jude hospital. His research interests include the study of mechanisms by which mutated E2A promote precursor B lymphoblastic leukemia, and ways to more precisely evaluate minimal residual disease (MRD) in acute myeloid leukemia by flow cytometry.
Rajen J. Mody, MD, MS
Dr. Mody is an Associate Professor in the Department of Pediatrics Hematology/Oncology at University of Michigan. Dr. Mody has an extensive experience in supervising investigator-initiated as well as group wide early-phase clinical trials as a principal investigator of several local and international clinical trials through the Children’s Oncology Group (COG). His research interests include studying the role of precision medicine in high risk pediatric malignancies through use of translational genomics and next-generation sequencing technology. In addition, his clinical research interests include use of innovative early-phase clinical trials for development of new agents against pediatric malignancies. He has also received formal training in clinical trials design and Biostatistics through a masters degree (M.S.) from the School of Public Health at the University of Michigan.
I. Elaine Allen, PhD
Dr. Allen is a Professor of Epidemiology & Biostatistics at UCSF. She founded and led several biotechnology companies including MetaWorks, an Evidence-Based Medicine firm; and Stat Systems, a diagnostic company. She previously held faculty positions at the University of Pennsylvania, Medical College of Pennsylvania, and Babson College. She is Co-Director of the Babson Survey Research Group and is actively involved in design and conduct of surveys on online education and entrepreneurship. Dr. Allen has published widely on statistical issues in meta-analysis, analytics, survey research, and clinical research methods.
Validation of fluorescence flow cytometry assays: post-analytic considerations Cytometry Part B 2013, 84B: 309-314.
Morphologic and immunophenotypic description of an unusual acute myeloid leukemia-associated translocation (8;19)(q24;q13.1) SH-EAHP Case of the Quarter, May 2013.
Morphoproteomic analysis of survival pathways in classical Hodgkin lymphoma IJCEM 2010, 3(1): 55-68.
Immunophenotypic features predictive of KIT activating mutations in t(8;21)/AML1-ETO acute myeloid leukemia AJCP 2007, 128: 550-557.
A teaching database for diagnosis of hematologic neoplasms using immunophenotypic by flow cytometry Arch Pathol Lab Med-Vol 132, May 2008.
For additional publications, visit the ResearchGate site here
DeePath’s SCALPEL (Single Cell Analysis of Limited Protein Expression Levels) assay is a multiplexed cell-based biomarker assay that measures oncogenic signaling activities in various cell types of a tumor sample.
When a growth factor or cytokine binds to its cell surface receptor, a cascade of tightly regulated signaling events ensues inside the cell through proteins within signaling cascades that get altered and activated by the addition of phosphate groups by kinases. Deregulated oncogenic pathways result from multiple protein kinases that get sequentially phosphorylated transmitting the signal into the nucleus, ultimately promoting unabated gene and protein expression. With the SCALPEL test, detailed characterization of the proliferative clone(s), cancer stem/progenitor cells, and the tumor-associated immunologic cells is performed by massively multiplexed immunophenotypic analysis to derive the signature of activated networks with single cell specificity.
SCALPEL is a high parameter cytometry application for more precise identification and characterization of different cell types comprising malignant neoplasms. Data analysis is performed by Eyelis analytics and data visualization software for statistical cell classification using multidimensional data.
The assay results are aimed to better characterize the stem/progenitor cell types that are typically resistant to standard therapies, and to decipher components of the immune environment for better response prediction. The SCALPEL results are integrated with routine diagnostic work-ups for more accurate classification, guided therapy selection, and monitoring of minimal residual disease (MRD) to improve the overall survival.
Our Eyelis analysis software allows for statistical classification of cells identified by cytometry and more intuitive data visualization.
ICSH/ICCS Working Group Practical Guidelines Meeting on Cell-based Fluorescence Assays for Laboratory Developed Tests (LDTs) – Part IV – Postanalytic Considerations 2011; Lucerne, ME. Cytometry Part B 2013; 84B: 309-14.
Personalized Medicine World Conference (PMWC) ’13, January 28-29; Mountain View, CA.
Mass Cytometry Analysis of Primitive Cell Subpopulations in Previously Treated Chronic Myeloid Leukemia in Chronic-Phase. Cancer Research: April 15, 2013; 73; 4118. Proceedings: AACR 104th Annual Meeting 2013, April 6-10; Washington, DC.
Functional characterization of Lymphoid Progenitor Cells in Chronic Myeloid Leukemia by Mass Cytometry Phos-flow Analysis. Podium Presentation (abstr. 25) International Society for Advancement of Cytometry CYTO XXVIII Annual Meeting ’13, May 19-22; San Diego, CA.
Multidimensional Data Visualization Tools for Multiparameteric Analysis of Signaling Pathways by Mass Cytometry Analyses of Chronic Myeloid Leukemia Specimens. Multimedia abstract (Program 128/B7) International Society for Advancement of Cytometry CYTO XXVIII Annual Meeting ’13, May 19-22; San Diego, CA.
Next Generation Diagnostics (Dx) Summit 2013, August 20-22, Capitol Hill; Washington, DC.
11th Annual Discovery on Target 2013, September 24-26; Boston, MA.
2013 Shanghai International Symposium on Cancer Stem Cells, October 17-19, Tongji University; Shanghai, China.
Multidimensional Single Cell Analysis of Diverse Cell-Types Comprising Malignant Neoplasms Using Mass Cytometry. Emerging Cell Technologies: Podium Presentation CMCB 2014 – BIT’s 4th Annual World Congress of Molecular and Cell Biology, April 25-28; Dalian, China.
Bio-IT World Conference & Expo ’14, April 29 – May 1, World Trade Center; Boston, MA.
Automated Analysis of High Parameter Cytometry Datasets to Classify and Characterize Distinct Cell Types in Biologic Samples of Cancerous and Inflammatory Disorders. Multimedia abstract (Program 140/B2) International Society for Advancement of Cytometry CYTO XXIX Annual Meeting ’14, May 17-21; Fort Lauderdale, FL.
Eyelis Software-Assisted Analysis of Proliferative Stem/Progenitor Cell Types Detected by the SCALPEL Assay in a Blood Sample with Relapsed Chronic Myeloid Leukemia. Diagnostics Section (Program 197/B66) 30th Congress of the International Society for Advancement of Cytometry CYTO Annual Meeting ’15, June 26-30; Glasgow, Scotland.
A Novel SCALPEL Cell-based Assay for Residual/Relapsed Disease Detection in Chronic Myelogenous Leukemia. International Clinical Cytometry Society Annual Meeting ’15, Oct 11-13; Denver, CO.
Automated Identification of Novel Cell Types Based Upon Signaling Characteristics in Chronic Myeloid Leukemia. Multimedia Abstract in Hematologic Disorders (B2). 31st Congress of the International Society for Advancement of Cytometry CYTO Annual Meeting ’16 , Jun 11-15; Seattle, WA.
Deepath Medical Diagnostics, Inc.
895 Dove St., Ste 300
Newport Beach, CA 92660
Although the company is not hiring at the moment, we would be interested in hearing from exceptional candidates for future job openings.